INCY vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Incyte Corporation exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a negligible Debt/Equity ratio of 0.01. The company is growing rapidly, with YoY revenue growth of 27.8% and earnings growth of 43.6%, while trading at a highly attractive PEG ratio of 0.34. Despite a bearish technical trend and insider selling, the current price of $95.72 sits significantly below the growth-based intrinsic value of $189.09. The combination of high ROE (29.87%) and strong liquidity makes this a compelling value-growth opportunity.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
INCY vs MRK: Head-to-Head Comparison
This page compares Incyte Corporation (INCY) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.